Spanish AIDS study group (GESIDA) and Secretariat of the Spanish National Plan on AIDS (spns) recommendations for antiretroviral therapy in HIV-infected adults: Year 2000 update (II);Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretrovírico en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2000 (II)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 18, Issue 8, 2000, Pages 396-412

  Miró, José M ^a   Antela, Antonio ^b   Arrizabalaga, Julio ^c   Clotet, Buenaventura ^d   Gatell, José M ^a   Guerra, Luis ^c   Iribarren, José Antonio ^c   Laguna, Fernando ^f   Moreno, Santiago ^b   Parras, Francisco ^e   Rubio, Rafael ^g   Santamaría, Juan Miguel ^h   Viciana, Pompeyo ⁱ  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Hospital Nuestra Senora de Aranzazu   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Plan Nacional Sobre el SIDA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Antiretroviral therapy; HIV infected adults; Year 2000 recomendations

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CROSS RESISTANCE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FETUS MALFORMATION; GENE AMPLIFICATION; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SYMPTOMATOLOGY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DISEASE PROGRESSION; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0034494175     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (264)

1. a ed.). Ministerio de Sanidad y Consumo. Madrid, 1995; 3: 1-12.
2. a ed.). Ministerio de Sanidad y Consumo. Madrid, 1997; 10: 1-16.
3. Grupo do Estudio de SIDA. Tratamiento antirretrovírico. Enf Infecc Microbiol Clin 1996; 14 (Supl 1): 1-52.
4. Moreno S, Arrizabalaga J, Gatell JM, Clotet B, Aguirrebengoa K, Antela A, et al, por el Grupo de Estudio de SIDA (GESIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Recomendaciones sobre tratamiento antirretroviral. Med Clin (Barc) 1998; 110: 109-116.
5. Moreno S, Arrizabalaga J, Gatell JM, Clotet B, Aguirrebengoa K, Antela A, et al, por el Grupo de Estudio de SIDA (GESIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbioiogía Clínica (SEIMC). Recomendaciones sobre tratamiento antirretroviral en 1998. Enferm Infecc Microbiol Clin 1998; 16: 374-376.
6. Carpenter C, Cooper D, Fischl M, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults. Updated recommendations of the IAS-USA Panel. JAMA 2000; 283: 381-390.
7. DHHS Panel on Clinical Practices for the treatment of HIV infection: Guidelines for the use of antiretroviral agents in HPV-infected adults and adolescents. Washington, enero 2000. En: http: //www.hivatis.org.
8. Pozniak A, Gazzard B, Churchill D, on behalf of the BHIVA Executive Committee. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. Londres, enero 2000. En: http: //www.aidsmap.com.
9. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999; 5: 512-517.
10. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antirretrovírico therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
11. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper D. Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodistrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999; 353: 2.093-2.099.
12. El Grupo de Estudio de Sida de la SEIMC, la Sociedad Española de Farmacia Hospitalaria y la Secretaría del Plan Nacional sobre el Sida. Recomendaciones para mejorar la adherencia al tratamiento antirretrovírico. Ministerio de Sanidad y Consumo, 1999.
13. Comisión Asesora del Plan Nacional sobre el SIDA. Resistencia a los fármacos antirretrovíricos. Madrid: Ministerio de Sanidad y Consumo, 1997.
14. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. N Engl J Med 1987; 317: 185-191.
15. Delta Coordinating Committe. Delta: a randomised double-blind controlled trial comparing combination of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283-291.
16. Hammer SM, Katzenstein DA, Hughes MD, Gundacker , Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. ACTG 175. N Engl J Med 1996; 335: 1.081-1.090.
17. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.
18. Cameron DW, Heath-Chiozzi M, Danner S, Cohem C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1997; 351 (9102): 543-549.
19. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS 1097; 11 (12): F101-105.
20. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336: 1.531-1.532.
21. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
22. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415-418.
23. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1.725-1.730.
24. Alberdi JC, López-Gay D, Farreras A, Nieto E. Descenso brusco de la mortalidad por VIH/SIDA en la Comunidad de Madrid. Med Clin (Barc) 1998; 110: 679.
25. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV infected adults with 200 to 500 CD4 cells per cubic millimeter. ACTG 175. N Engl J Med 1996; 335: 1.091-1.098.
26. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 834: 426-431.
27. Hirsch M, Brun-Vézinet F, D'Aquila R, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000; 283: 2.417-2.426.
28. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus infected subjects treated with HIV specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321-329.
29. Haynes BF, Pantaleo G. Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271: 324-328.
30. Plana M, García F, Gallart T, Miró JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Lancet 1998; 352: 1.194-1.195.
31. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 523).
32. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996; 334: 701-706.
33. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339: 33-39.
34. Berrey MM, Schacker TS, Collier AC, Shea T, Brodie SJ, Coombs R, Corey L. Clinical impact of treatment of primary HIV-1 infection with zidovudine, lamivudine and indinavir: a cohort study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract 1684).
35. + T cell responses associated with control of viremia. Science 1997; 278: 1.447-1.450.
36. Markowitz M, Jin X, Ramratnam B, Hurley A, Chen D, Bauer D, et al. Virologic and immunologic profiles of newly infected individuals electing discontinuation of HAART after approximately three years of apparently suppressive therapy. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco 1999 (Abstract LB-16).
37. th European Conference on Clinical Aspects and Treatment of HIV-infection. Lisboa, Portugal: 1999 (Abstract 230).
38. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 552).
39. th European Conference on Clinical Aspects and Treatment of HIV-infection. Lisboa, Portugal: 1999 (Abstract 519).
40. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 12).
41. Li TS, Tubiana R, Katlama C, Calvez V, Mohand HA, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1.682-1.686.
42. Kostense S, Raaphorst FM, Notermans DW, Joling J, Hooibrink B, Pakker NG, et al. Diversity of the T-cell receptor BV repertoire in HIV-1 infected patients reflects the biphasic CD4+ T cell repopulation kinetics during highly active antiretroviral therapy. AIDS 1998; 12: F235-F240.
43. Peña JM, Miró JM. Restauración inmunológica en pacientes con Sida. ¿Requiem por las profilaxis? Med Clín (Barc) 1999; 113: 375-378.
44. Mellors J, Munoz AM, Giorgi JV. Plasma vírica load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126: 946-954.
45. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177: 40-47.
46. Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, et al. Sex differences in HIV-1 vírica load and progression to AIDS. Lancet 1998; 352: 1.510-1.514.
47. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180: 666-672.
48. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17): 1-19.
49. García F, Romeu J Grau I, Sambeat MA, Dalmau D, Knobel H, et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease the Spanish Earth-1 Study. AIDS 1999; 13: 2.379-2.388.
50. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract LB-22).
51. Staszewski S, Morales-Ramirez J, Tashima TK, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1.865-1.873.
52. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract 505).
53. th European Conress of Clinical Microbiology and Infectious Disseases. Stockholm, Swedwn. 28-31 May, 2000 (Abstract WeP253). Clin Microbiol Infect 2000; 6 (Supl 1): 139.
54. Crowe SM, Carlin JB, Stewart KT, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistics infections and malignancies in HIV infected persons. AIDS 1991; 4: 770-776.
55. Miró JM, Buira E, Mallolas J, Gallart T, Moreno A, Zamora L, et al. Linfocitos CD4+ e infecciones oportunistas y neoplasias en pacientes con infection por el VIH. Med Clin (Barc) 1994; 102: 560-570.
56. Anónimo. Fármacos para la infección por el VIH. Medical Letter (Ed. esp) 2000; 22: 17-22.
57. a ed.). Barcelona: Masson-Salvat, 2000.
58. a ed.). Madrid: Idepsa, 1999.
59. a ed.). Barcelona: Ediciones Permanyer, 2000.
60. Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyerr GA, Fisher RL, et al. Efficacy, safety and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000; 14: 671-681.
61. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Wainberg MA, et al. Randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998; 279: 930-937.
62. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract I1978).
63. th Conference on Retroviruses and Oppotunistic Infections. Chicago IL: 1999 (Abstract # 628).
64. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Pérez J, Pérez JL, et al. Preliminary results of a randomized, multicenter study comparing Combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients (COMBINE study). 7th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract # 510).
65. th European Congress of Clinical Microbiology and Infectious Dieseases. Stockholm, Sweden: 2000 (Abstract WeP252). Clin Microbiol Infect 2000; 6 (Supl 1): 139.
66. Dybul M, Chun TW, Ward DJ, Hertogs K, Larder B, Fox CH, et al. Evaluation of lymph node vírica burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease-inhibitor sparing highly active antiretroviral regimen. J Infect Dis 200; 181: 1.276-1.279.
67. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract #I1982).
68. New study shows efavirenz effective with d4T and 3TC. AIDS Alert 1999; 14:60.
69. Para M, Conway B, Green S, Daly P, Stapleton J, Wathen L, et al. Safety and efficacy of delavirdine (DLV) in combination with zidovudine (ZDV) and lamivudine (3TC): final 52-week analysis. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract #I1979).
70. Kakuda TN, Page JM, Henry K, Schacker T, Acosta EP, Anderson PL, et al. Concentration-controlled (CC) antiretroviral therapy with zidovudine (ZDV), lamivudine (3TC) and indinavir (IDV): pharmacokinetics and safety. 6th Conference on Retroviruses and Oppotunistic Infections. Chicago IL: 1999 (Abstract 368).
71. th European Conference on Clinical Aspects and treatment of HIV-Infection. Lisboa, Portugal: 1999 (Abstract 205).
72. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incedence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune defic Syndr Hum Retrovirol 2000; 23: 236-245.
73. th European Conference on Clinical Aspects and treatment of HIV-Infection. Lisboa, Portugal: 1999 (Abstract 601).
74. Murphy RL, Gulick RM, De Gruttola V, D'aqiula RT, Eron JJ, Sommadossi JP, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 1999; 179: 808-816.
75. th Conference on Retroviruses and Oppotunistic Infections. Chicago. IL: 1999 (Abstract 630).
76. th Conference on Retroviruses and Oppotunistic Infections. Chicago, IL: 1999 (Abstract 363).
77. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract #321).
78. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract # 512).
79. th European Conference on Clinical Aspects and treatment of HIV-Infection. Lisboa, Portugal: 1999 (Abstract 830).
80. th International Workshop on Drug Resistance and Treatment Strategies. 12-16 June 2000, Sitges (Spain) (Abstract 38). Antiviral Ther 2000; 5 (Supl 3): 29.
81. th International Workshop on Drug resistance and Treatment Strategies. 12-16 June 2000, Sitges (Spain) (Abstract 39). Antiviral Ther 2000; 5 (Supl 3): 30.
82. Kempf D, Rode R, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, et al. Duration of vírica suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14.
83. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma vírica load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS 1998; 12: 1.619-1.624.
84. th Conference on Retroviruses and Opportunistic Infections; Chicago, IL: 1998 (Abstract 509).
85. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72: 2422-2428.
86. th International Workshop on Drug Resistance and Treatment Strategies. Sitges (Spain), 12-16 June 2000 (Abstract 112). Antivíral Ther 2000; 5 (Supl 3): 89.
87. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV vírica load markers in clinical practice. Nat Med 1996; 2: 625-629.
88. Brambilla D, Reichelderfer PS, Bremer JW, Shapiro DE, Herschow RC, Katzenstein DA, et al. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. AIDS 1999; 13: 2.269-2.279.
89. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic. AIDS 1999; 13: F35-F43.
90. th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1999 (Abstract 494).
91. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4 + cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) Swiss HIV Cohort Study. Lancet 1998; 351: 723-724.
92. García F, Vidal M, Plana M, Cruceta A, Gallart T, Pumarola T. Residual low-level vírica replication could explain discrepancies between vírica load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy Clin Infect Dis 2000; 30: 392-394.
93. Anónimo. Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection. MMWR Morb Mortal Wkly Rep 1992; 41: 1-19.
94. Sax PE, Boswell SL, White-Guthro M, Hirsch MS. Potential clinical implications of interlaboratory variability in CD4+ T-lymphocyte counts of patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1.121-1.125.
95. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351: 228-230.
96. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1.443-1.445.
97. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351: 252-255.
98. Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JF, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12: 1.815-1.822.
99. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2.220-2.226.
100. th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 (Abstract 92).
101. Chesney M, Ickovics J, for the Recruitment, Adherence and Retention Committee of the ACTG. Adherence to combination therapy in AIDS clinical trials. Washington, DC, Annual Meeting of the AIDS Clinical Trials Group, 1997.
102. a ed.). Barcelona: Ediciones Doyma SA, 1998: 281-296.
103. th Conference on Retroviruses and Opportunistic Infections. Chicago: 1998 (Abstract 362).
104. th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 (Abstract 487).
105. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237-242.
106. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drags. Nat Med 1999; 5: 1.048-1.051.
107. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Internat Antiviral News 2000; 8: 65-91.
108. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA. Deutsch P, et al. vírica dynamics in HIV-1 infection. Nature 1995; 373: 123-126.
109. th International Workshop on Drug Resistance and Treatment Strategies. Sitges (Spain), 12-16 June 2000 (Abstract 52). Antiviral Ther 2000; 5 (Supl 3); 38.
110. th Conference of Retroviruses and Opportunistic Infections. San Francisco: 1999 (Abstract 489).
111. Schock HB, Garsky VM, Kuo LC. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem 1996; 271: 31.957-31.963.
112. th ICAAC. San Francisco: 1997 (Abstract 21).
113. Schapiro JM, Winters MA, Lawrence J, Merigan TC, et al. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and mdinavir and correlations with genotypic mutations. AIDS 1999; 13: 359-365.
114. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who have previously failed nelfinavir. AIDS 1999; 13: F23-F28.
115. Condra JH, Holder DJ, Schlief WA, Blahy OM, Danovich RM, Gabryelski LJ, et al. Genetic correlates of in vivo vírica resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virology 1996; 70: 8.270-8.276.
116. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations to HIV-1 protease confers resistance to ritonavir. Nat Med 1996; 2: 760-766.
117. Deeks SG, Grant RM, Beatty G, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998; 12: F97-F102.
118. th World AIDS Conference. Geneva: 1998 (Abstract 12330).
119. th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 (Abstract 400).
120. th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 (Abstract 490).
121. th International Congress on Drug Therapy in HIV Infection. Glasgow, 1998; AIDS 1998; 12 (Supl 4): S13.
122. th International Congress on Drug Therapy in HIV Infection. Glasgow. AIDS: 1998; 12 (Supl 4): S40.
123. th ICAAC, San Diego: 1998 (Abstract 1-201).
124. Garraffo R, Durant J, Clevenbergh PI, Icard S, Shapiro JM, Dellamonica P. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy. Antiviral Ther 1999; 4 (supl 1): 75 (Abstract 109).
125. th International Workshop on drug Resistance and Treatment Strategies. Sitges (Spain), 12-16 June 2000 (Abstract 4). Antiviral Ther 2000; 5 (Supl 3): 4.
126. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study AIDS 1999; 13: F17-F21.
127. th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 (Abstract 130).
128. Montaner JS, Harrigan R, Jahnke N, et al. Multidrug rescue therapy (MDRT) for HIV-infected individuals with prior virologic failure to multiple regimens (abstract). Antiviral Ther 1998; 3 (Supl 5): 80.
129. Montaner JSG, Zala C, Conway B, Raboud J, Patenaude P, Rae S, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997; 175: 801-806.
130. Rossero E, Nokta M, Andron L, Pollard R. Combination therapy with stavudine, didanosine and hydroxiurea in nucleoside-experienced HIV-1-infected individuals: a preliminary report. Antiviral Ther 1997; 2 (Supl 3): 119-123.
131. García F, Plana M, Vidai C, Cruceta A, O'Brien W, Pantaleo G, et al. Dynamics of vírica load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13: F79-P86.
132. Ruiz L, Martínez-Picado J, Romeu R, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically-HIV-1 infected patients after long-term vírica suppression. AIDS 14: 397-404.
133. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000. (Abstract LB 10).
134. Miller V, Rottman C, Hertogs K. Mega-HAART, resistance and drug holidays. Toronto: 2nd International Workshop on Salvage Therapy for HIV infection, 1999.
135. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaut JA, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998; 339: 1.269-1.276.
136. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339: 1.261-1.268.
137. Reijers MHE, Weverling GJ, Jurriaans S, Wit FW Weigel HM, Ten Kate RW, et al. Maintenance therapy after quadruple induction herapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185-190.
138. Weverling GJ, Lange JMA, Juriaans S, Prins JM, Lukashov VV, Notermans DW, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998; 12: F117-F122.
139. Cooper DA, Emery S. Therapeutic strategies for HIV infection. Time to think hard. N Engl J Med 1998; 339: 1.319-1.321.
140. Casado JL, Pérez Elías MJ, Antela A, Sabido R, Martí-Belda P, Dronda F, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998; 12: F131-F135.
141. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1.881-1.883.
142. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
143. Martinez E, Gatell JM. Metabolic abdnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr Op Infect Dis 1999; 12: 13-19.
144. Brinkman K, Kakuda TN. Mitocondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Cur Opin Infect Dis 2000; 13: 5-11.
145. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract #I2064).
146. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract #I2198).
147. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 50).
148. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 206).
149. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 (Abstract #I510).
150. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 48).
151. Drake JW. Rates of spontaneous mutations among RNA viruses. Proc Natl Acad Sci USA 1993; 90: 4.171-4.175.
152. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutations. Genetics, 1998; 148: 1.667-1.686.
153. Mansky L, Temin H. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5.087-5.094.
154. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
155. Wei XP, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Nature 1995; 373:117-122.
156. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-489.
157. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and vírica generation time. Science 1996; 271: 1.582-1.586.
158. Wain-Hobson S. Is antigenic variations of HIV important for AIDS and what might be expected in the future? En: Morse SS, ed. The Evolutionary Biology of Viruses. New York: Raven Press, 1994; 185-209.
159. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons terated with lamivudine (3TC). J Infect Dis 1995; 171: 1.411-1.419.
160. Richman D. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. Am J Med 1990; 88: 8S-10S.
161. Condra JH, Holder D, Schleif W, Blahy OM, Danovich RM, Gabryelski LJ, et al. Genetic correlates of in vivo vírica resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70: 8.270-8.276.
162. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers reistance to ritonavir. Nature Med 1996; 2: 760-766.
163. Kuritzes DR. Drug resistance testing: time to be used in clinical practice? AIDS Rev 1999; 1: 45-50.
164. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-F127.
165. th International Workshop pn Drug resistance and Tratment Strategies. Sitges (Spain), 12-16 June 2000 (Abstract 62). Antiviral Ther 2000; 5 (Supl 3): 49.
166. th International Workshop on Drug resitance and Treatment Strategies. Sitges (Spain), 12-16 June 2000 (Abstract 63). Antiviral Ther 2000; 5 (Supl 3): 49.
167. Yerly S, Kaiser L, Race E, Bru J, Clavel F, Perrin L. Transmission of antiretroviral-resistant HIV-1 variants. Lancet 1999; 354: 729-733.
168. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282: 1.135-1.141.
169. Little S, Daar E, D'Aquila R, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282: 1.142-1.149.
170. Brodine S, Shaffer R, Starkey M, Tasker Sa, Gilcrest JL, Louder MK, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999; 131: 502-506.
171. Salomon H, Wainberg M, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000; 14: F17-F23.
172. Wegner S, Brodine S, Mascola J, Barile A, Aronson N, Martin G, et al. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy-naive individuals. Antiviral Ther 1999; 4 (Supl 1): 85 (Abstract 119).
173. Verbiest W, Schel P, Conant M, Van den Btoeck R, Bloor S, Alcorn T, et al. An epidemiological prospective survey assessing the prevalence of HIV-1 drug resistance in 230 HIV-1-positive antiretroviral-naive patients from the USA. Antiviral Ther 1999; 4 (Supl 1): 86-87 (Abstract 122).
174. Descamps D, Costagliola D, Glaude G, Buffet-Janvresse C, Calvez V, Collin G, et al. Prevalence of resistance mutations in antiretroviral-naive patients. Antiviral Ther 1999; 4 (Suppl 1): 87 (Abstract 123).
175. Harrigan PR, Alexander C, Dong W, Jahnk N, O'Shaughnessy M, Montaner JS. Prevalence of resistance-associated mutations in patients starting antivirals. Antiviral Ther 1999; 4 (Suppl 1): 88 (Abstract 124).
176. Miró JM, Pumarola T, García F, Arnedo M, Vidal C, Lozano L, et al. Prevalence of transmission of HIV-1 drug resistant mutations in patients with primary HIV-1 infection in Barcelona (Spain). XIII International AIDS Conference. Durban (South Africa): 2000.
177. Briones C, Rodríguez C, Del Romero J, Soriano V. Primary genotypic and phenotypic resistance to antiretroviral drugs in recent seroconverters in Madrid. AIDS 2000 (en prensa).
178. Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12: 1.015-1.020.
179. Puig T, Pérez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 2000; 14: 727-732.
180. D'Aquila R, Johnson VA, Welles S, Japour AJ, Kuritzkes DR, De Gruttola V, et al. Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401-408.
181. Japour A, Welles S, D'Aquila R, Johnson VA, Richman DD, Coombs RW, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J Infect Dis 1995; 171: 1.172-1.179.
182. Kozal M, Shafer R, Winters M, Katzenstein DA, Merigan TC. HIV-1 syncitium-inducing phenpotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr Hum retrovirol 1994; 7: 832-838.
183. Havlir D, Petropoulos C, Hellmann N, Whitcomb JM, Richman DD, the ACTG 343 Team. Evolution of drug resistance associated with loss of vírica supression in patients treated with indinavir, lamivudine and zidovudine (Abstract 74). Antiviral Ther 1998; 3 (Supl 1): 52-53.
184. Descamps D, Calvez V, Flandre P, Pialoux G, Raffi F, Delaugerre C, et al. Genotypic resistance analyses of plasma HIV-1 RNA in patients failing to the maintenance therapy in Trilege trial (Abstract OP3.3). AIDS 1998; 12 (Supl 4): S11.
185. Zolopa AR, Shafer RW, Warford A, Montoya JG, Katzenstein D, Merigan TC, et al. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype (Abstract 54). Antiviral Ther 1998; 3 (Supl 1): 37.
186. Deeks SG, Parkin N, Petropoulos C, Grant RM, Volberding PA, Whitcomb J, et al. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy (Abstract 53). Antiviral Ther 1998; 3 (Supl 1): 36.
187. Patick A, Zhang M, Hertogs K, Griffiths L, Mazabel E, Pauwels R, et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program (Abstract 57). Antiviral Therapy 1998; 3 (Supl 1): 39.
188. Harrigan P, Montaner J, Hogg E, Yip B, Hertogs K, Pauwels R, et al. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a comunity setting (Abstract 55). Antiviral Ther 1998; 3 (Supl 1): 38.
189. Lanier R, Danehower S, Daluge S, Cutrell A, Tisdale M, Pearce G, et al. Genotypic and pbenotypic correlates of response to abacavir (ABC, 1592) (Abstract 52). Antiviral Ther 1998; 3 (Supl 1): 36.
190. Durant J, Clevenbergh P, Halfon P, Del Giudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy. Lancet 1999; 353: 2.195-2.199.
191. Clevenbergh P, Durant J. Halfen P, del Giudice P, Simonet P, Montagne N, et al. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing HAART. Antiviral Ther 1999; 4 (Supl 1): 42 (Abstract 60).
192. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther 1999; 4 (Supl 1): 43 (Abstract 61).
193. th International Workshop on Drug Resistance and Treatment Strategies. Sitges (Spain), 12-16 June 2000 (Abstract 84). Antiviral Ther 2000; 5 (Supl 3): 67.
194. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatrics AIDS Clinicals Trials Group Study 185 Team. N Engl J Med 1999; 341: 385-393.
195. Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS 2000; 14: 263-271.
196. Plan Nacional del SIDA. Las resistencias a los fármacos antirretrovíricos: Utilización de los tests en la práctica asistencial. Madrid: 1997.
197. Ledesma E, Soriano V, on behalf of the Spanish Drug Resistance Panel. Spanish consensus on drug resistance testing in clinical practice. AIDS 1999; 13:1.998-2.001.
198. Knobel H, Carmona A, Grau S, Pedro-Botet J, Díez A. Adherence and Effectiveness of Highly Active Antiretroviral Therapy. Arch Intern Med 1998; 158: 1.953.
199. Rodríguez-Rosado R, Jiménez-Nacher I, Soriano V, Anton P, Gonzalez-Lahoz J. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS 1998; 12: 1.112.
200. th European Conference on Clinical Aspects and treatment of HIV-Infection. Lisboa, Portugal: 1999 (Abstract 511).
201. th European Conference on Clinical Aspects and treatment of HIV-Infection, Lisboa: 1999 (Abstract 857).
202. th European Conference on Clinical Aspects and treatment of HIV-Infection. Lisboa: 1999 (Abstract 516).
203. Codina C, Knobel H, Miró JM, Carmona A, Garcia B, Antela A, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretrovírico. Farm Hosp 1999; 23: 215-229.
204. Knobel H, Codina C, Miró JM, Carmona A, Garcia B, Antela A, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretrovírico. Enf Infecc Microbiol Clin 2000; 18: 27-39.
205. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 59).
206. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 56).
207. th Conference on Retroviruses and Oppotunistic Infections. San Francisco, CA,: 2000 (Abstract 57).
208. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 17).
209. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno P, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-1667.
210. Jiménez-Nacher I, Soriano V, Bruno F, Rouviere O, Lang JM, et al. Interactions of antiretroviral drugs. AIDS Rev 1999; 1: 116-125.
211. Fuertes A, Otero MJ. Interacciones de los fàrmacos antirretrovíricos. Med Clin (Barc) 1999; 113: 94-102.
212. Tuset M, Miró JM, Codina C, Del Cacho E, Ribas J. Interacciones entre los antirretrovíricos y los fármacos utilizados en el tratamiento de la tuberculosis. Enf Emerg 2000; 2: 16-32.
213. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000; 49: 185-189.
214. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract 88).
215. th Conference on Retroviruses and Oppotunistic Infections. San Francisco: 2000 (Abstract LB6).
216. Piscitelli SC, Burstein AH, Chaitt D, Alfaro EM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355: 547-548.
217. Jayasekara B, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG. Antiviral therapy for HIV patients with renal insuficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1993; 21: 384-395.
218. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1.173-1.180.
219. Centers for Disease Control and Prevention. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission-Thailand, 1996-98. MMWR Morb Mortal Wkly Rep 1998; 47: 151-154.
220. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1.409-1.414.
221. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-2): 1-30.
222. th Conference on Retroviruses and Opportunistic Infections. Washington DC: 1997 (Abstract 607).
223. Mirochnick M, Fenton T, Gagnier P, Par J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998; 178: 368-374.
224. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.
225. Marseille E, Kahn J, Mmiro F, Guay L, Musoke P, Fowler MG, Jackson JB. The cost-effectiveness of a single dose nevirapine regimen to mother and infant to reduce vertical HIV transmission in Uganda. Lancet 1999; 354: 803-809.
226. Beeker-Pergola G, Guay L, Mmiro F, Musoke P, Fung S, Jackson JB, Eshleman SH. Selection of the K103 nevirapine (NVP) resistance mutation in Ugandan women receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-006). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco: 2000 (Abstract 658).
227. Shapiro D, Tuomala R, Samelson R, Burshett S, Ciupak G, McNamara J, et al. Antepartum Antiretroviral Therapy and Pregnancy Outcomes in 462 HIV-infected Women in 1998-1999 (PACTG 367). 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, C.A. Abstract 664.
228. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtian G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1.084-1.089.
229. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12: F241-247.
230. Coll O, Martínez de Tejada B, Cararach C. Estrategia terapéutica en la gestacion VIH positiva. Folia Clínica en Obstetricia y Ginecología. Barcelona: Ediciones Doyma, 1999.
231. Sperling RS, Shapiro DE, Coombs EW, Todd JA, Herman SA, McSherry GD, et al. Maternai vírica load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus tyoe 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl J Med 1996; 335: 1.621-1.629.
232. Parazzini F, for the European Mode of Delivery Collaboration. Elective cesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized controlled trial. Lancet 1999; 353: 1.035-1.039.
233. O'Sullivan MJ, Scott G, yasin S, Mitchell C, Scott W, Duthely M. Protease inhibitors: is preterm delivery a risk? Am J Obstet Gynecol 1999; 180: S105 (Abstract 353).
234. Stek A, Kramer F, Fassett M, Khoury M. The safety and efficacy of protease inhibitor therapy for HIV infection during pregnancy. Am J Obstet Gynecol 1999; 180: S6 (Abstract 14).
235. The European Collaborative Study. Caesarean section and risk of vertical transmission of HIV-1 infection. Lancet 1994; 343: 1.464-1.467.
236. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280: 55-60.
237. Kind C, for the Paediatric AIDS Group of Switzerland. Mother-to-child transmission of human immunodeficiency virus type 1: influence of parity and mode of delivery. Eur J Pediatr 1995; 154: 542-545.
238. Tovo P-A, de Martino M, Gabiano C, Galli L, Cappello N, Ruga E, et al. Mode of delivery and gestational age influence perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 88-94.
239. Mandelbrot L, Mayaux M-J, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla JL, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. Am J Obstet Gynecol 1996; 175: 661-667.
240. Thomas PA, Weedon J, Kransinski K, Abrams E, Shafler N, Matheson P, et al. Maternal predictors of perinatal human immunodeficiency virus transmission. Pediatr Infect Dis J 1994; 13: 489-495.
241. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334: 1.617-1.623.
242. Simonds RJ, Steketee R, Nesheim S, Matheson P, Palumbo P, Alger L, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV: Perinatal AIDS Collaborative Transmission Studies. AIDS 1998; 12: 301-308.
243. Dunn DT, Newell M-L, Mayaux MJ, Kind C, Hutto C, Goedert JJ, et al. Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. J Acquir Immune Syndr Hum Retrovirol 1994; 7: 1.064-1.066.
244. Read JS, for the International perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977-987.
245. Stringer JSA, Rouse DJ, Goldenberg RL. Prophylactic Cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission. The case for restraint. JAMA 1999; 281: 1.946-1.949.
246. th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 (Abstract 686).
247. Schuitemaker N, van Roosmalen J, Dekker G, van Dongen P, van Geijn H, Gravenhorst JB. Maternal mortality after cesarean section in The Netherlands. Acta Obstet Gynecol Scand 1997; 76: 332-334.
248. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997; 102 (Supl 5B): 9-15.
249. Ippolito G, Puro V, De Carli G, the Italian Study Group on Occupational Risk of HIV Infection. The risk of occupational human immunodeficiency virus infection in health care workers. Arch Intern Med 1993; 153: 1.451-1.458.
250. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337: 1.485-1.490.
251. Grob PM, Cao Y, Muchmore B, Ho DD, Norris S, Pav JW, et al. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat Med 1997; 3: 665-670.
252. Expert Advisory Group on AIDS. Guidelines on post-exposure prophylaxis for health care workers occupationally exposed to HIV. London: Department of Health, 1997.
253. Gerberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996; 125: 497-501.
254. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 1996; 45: 468-472.
255. Centers for Disease Control and Prevention. Public Health Service Guidelines for the Management of Health-Care Worker Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR Morb Mortal Wkly Rep 1998; 47: RR-7.
256. Centers for Disease Control and Prevention. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults. MMWR Morb Mortal Wkly Rep 1998; 47: RR-5.
257. Tack P, Bremer J, Harris A, Landay A, Kessler H, Kuritzkes D. Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. JAMA 1999; 281: 1.085-1.086.
258. Parkin JM, Murphi M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355: 722-723.
259. Puro V for the Italian Registry of Post-Exposure Prophylaxis. Post-Exposure Prophylaxis for HIV infection. Lancet 2000; 355: 1.556-1.557.
260. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5: 1.116-1.118.
261. Tokars JI, Marcus E, Culver DH, Schable CA, McKibben PS, Bandea CI, Bell DM, for the CDC Cooperative Needlestick Surveillance Group. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993; 118: 913-919.
262. Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS 1996; 10 (Supl A): S75-S82.
263. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997; 336: 1.097-1.099.
264. Centers for Disease Control and Prevention. Management of Possible Sexual, Injecting Drug-Use, or Other Nonoccupational Exposure to HIV, Including Considerations Related to Antiretroviral Therapy. MMWR Morb Mortal Wkly Rep 1998; 47: RR-17.